Skip to content

Pulmonary Hypertension on Prognosis of Acute Myocardial Infarction Patients With Reduced Left Ventricular Function

Pulmonary Hypertension on Prognosis of Acute Myocardial Infarction Patients With Reduced Left Ventricular Function (STIMULATE): A Single-center, Retrospective Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06186713
Acronym
STIMULATE
Enrollment
4784
Registered
2024-01-02
Start date
2023-03-30
Completion date
2023-08-01
Last updated
2024-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction, Pulmonary Hypertension

Keywords

Acute Myocardial Infarction, Pulmonary Hypertension

Brief summary

Pulmonary hypertension (PH) has a negative effect on acute myocardial infarction (AMI) patients and appears to be closely associated with reduced left ventricular function. However, its impact on AMI patients with reduced left ventricular function remains unclear. This retrospective study included AMI patients with reduced left ventricular function to investigate the prognostic value of PH in this specific type of patient. Meanwhile, a nomogram would be established basing on the identified independent risk factors, hoping to provide a novel risk stratification for them.

Interventions

OTHERThis was an observational study, and no Intervention was given to the patients.

This was an observational study, and no Intervention was given to the patients.

Sponsors

First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* The patients who were hospitalized for AMI with reduced left ventricular function at the First Affiliated Hospital of Jiaotong University from January 2018 to January 2022.

Exclusion criteria

* Myocardial infarction complicated by cardiac rupture. * Significant pre-existing heart failure. * Other comorbidities such as malignancy that may significantly affect prognosis. * Incomplete clinical data.

Design outcomes

Primary

MeasureTime frameDescription
The incidence of all-cause death1-year after the AMI.All-cause death will be determined by clinical records or phone calls with patients and their family.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026